GH Secretagogue
CJC-1295
CJC-1295 (Modified GRF 1-29)
Evidence tier: Human clinical trials exist. Phase II data for GHRH analog activity.
| Molecular weight | 3647.3 Da |
| Molecular formula | C165H269N47O46 |
| CAS number | 863288-34-0 |
| Half-life | ~6–8 days (DAC form); ~30 minutes (no-DAC / Mod-GRF 1-29) |
| Administration | subcutaneous |
| Research dose | 1–2 mg per week (DAC form). Often paired with Ipamorelin. |
Amino Acid Sequence
Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 (DAC form)
Primary Mechanism
GHRH receptor agonism — stimulates pituitary GH release
Studied For
growth hormone secretionbody compositionsleep qualityrecovery
Reconstitution
Reconstitute with bacteriostatic water. For a 2 mg vial add 1 mL BW for a 2,000 µg/mL solution.
Storage
Lyophilised: store at -20°C. Reconstituted: refrigerate at 2–8°C, use within 30 days.
Notes
DAC (Drug Affinity Complex) version has extended half-life via albumin binding. No-DAC version (Mod-GRF 1-29) has short half-life and is typically dosed pre-sleep. Commonly stacked with Ipamorelin for synergistic GH pulse.
This page contains affiliate links. If you purchase through these links, I may earn a commission at no extra cost to you.
These products are sold for research purposes only and are not intended for human consumption.